Tag Archives: blue

Navigating Water ETFs

There is an impending water shortage, resulting in investment opportunities. Water ETFs provide a safer, albeit expensive, way to invest in the fragmented water industry. FIW has the best holdings, but a potentially very expensive fee structure. CGW offers nice global exposure to water investments and is my favorite of the four ETFs. PHO and PIO have a surprisingly strong emphasis on alternative energy. THE WATER OPPORTUNITY For several years I have followed an investing thesis I believe will significantly outperform the broader market: water. Water is essential to all forms of known life. Humans are particularly dependent on water. Without it we die within a week, and most die in three or four days. However, humankind’s uses for water extend way beyond drinking, or even household consumption such as cooking, bathing, or cleaning. Agriculture accounts for an impressive 70% of global water use; other vital industries such as mining , oil and gas , hydroelectric power, and general manufacturing are all highly water intensive. The dire water situation becomes even more evident when the future is taken into account. For one, shifting weather patters associated with climate change will likely cause dry areas to face more frequent and persistent droughts. Even more importantly, today’s global population is expected to jump from the current 7 billion people to 9 billion by 2040 . The extra 2 billion people on the planet, along with a rapidly growing global middle-class , will increase demand for water and the vital goods (food, energy, materials, and technology) it produces. With these facts in mind, let’s consider the global water situation . 97.5% of water is salt water in the oceans. Of the remaining 2.5% of water that is fresh, over half (~69%) is locked up in glaciers and snowpack. If global temperatures increase as expected over the next 85 years (between 2° and 11.5° F) , we can expect a significant amount of this fresh water to melt, flow into oceans, and become salt water. Of the ~0.8% of Earth’s water that is fresh and liquid, a significant amount is also polluted, especially in developing countries. So despite all the blue that you see on a picture of Earth from space, a generous estimate would render only about 0.67% of it immediately ready for human use, with several trends working to reduce that percentage even further. HOW TO GO ABOUT INVESTING IN WATER The water industry is very fragmented, meaning that investors should tread with caution-there is no “Exxon” of the water industry, where you can simply park your money with a dominant player. While there are many companies in this sector that I am very bullish on, the fragmented nature of the water industry makes it a prime candidate for ETF investments. In this article I will give my thoughts on the four water ETFs: First Trust Water Index (NYSEARCA: FIW ), Guggenheim S&P Global Water Index (NYSEARCA: CGW ), PowerShares Water Resources Portfolio (NYSEARCA: PHO ), and PowerShares Global Water Portfolio (NYSEARCA: PIO ). MEET THE ETFs FIW: This ETF is by far my favorite in terms of holdings and organization. First Trust gave FIW a strong weighting towards industrials (60%); Utilities account for 25% of the ETF, and IT, materials, and healthcare comprise the other 15% of the portfolio. I am particularly partial to this fund because Lindsay (NYSE: LNN ), my favorite play in the water industry, is its top holding. For those interested, last fall I wrote an article about Lindsay. PICO Holdings (NASDAQ: PICO ), which accounts for 1% of the fund, may raise some eyebrows because it is labeled as a financial. PICO is technically a financial (it is an insurance company), but it owns valuable water rights in Arizona and Nevada, hence its inclusion in the ETF. Source: First Trust I favor water ETF’s with strong industrial weightings, along with IT, materials, and health care, because these companies generally have reasonable OpEx and face very little regulatory oversight, meaning they are in prime condition to profit from investment in water infrastructure. On the other hand, water utilities have high OpEx and must have regulatory approval for rate increases. Granted, utilities provide income and stability, but my goal for water stocks is growth, rather than a bond substitute. This said, FIW’s organization provides some risk mitigation. Of FIW’s 37 holdings, none account for more than 4.5% of the portfolio, and none account for less than 1% of the portfolio (top 10 assets account for 41% of the fund). Almost all are American companies, and all trade on the NYSE or NASDAQ. (click to enlarge) Source: First Trust While there is a lot to like about FIW, it does have some flaws. For one, its dividend yield is only 0.74%. As I mentioned, I expect little in the ways for yield when investing in water, but a yield between 1%-2% would be better. FIW’s average daily trade volume of 57.5K is another potential red flag for investors, though PHO is the only other water ETF with a higher average volume. Finally, and most disappointingly, FIW will very likely assume a very high expense ratio. For the moment, its 0.59% expense ratio is actually the lowest of the four ETFs. However, the prospectus states that the true expense ratio is 0.84%, but that First Trust has agreements to keep the fees at or below 0.60% “at least through April 30, 2016.” Though it seems the fee reimbursement could continue beyond this date, investors need to be prepared for an almost 50% increase in the expense ratio within the next year. FIW trades 0.13% below its net asset value, so maybe the market has already factored in some degree of a discount. CGW: Guggenheim’s water ETF truly provides global exposure: only 38% of the fund is based in the US. The top domestic holdings are Pentair (NYSE: PNR ), Danaher (NYSE: DHR ), American Water Works (NYSE: AWK ), and Xylem (NYSE: XYL ). Global utility behemoths such as Veolia SA ( OTCPK:VEOEY ), United Utilities Group PLC, Severn Trent PLC, and Suez Environnement SA account for some of the top foreign assets. Although CGW has 50 holdings, it is weighted quite heavily towards the top holdings, as the top 10 account for 52% of the fund. I would prefer the allocation to be more diversified, but the majority of the top holdings fit the water theme very well (I consider IDEX a bit of a stretch, but understand Guggenheim reasoning of wanting to give water metering meaningful inclusion). Source: Guggenheim 40% of CGW’s holdings are in utilities, which is a higher percentage than I would prefer. However, the weighting towards utilities provides a nice counterbalance to the volatility that comes with investing in foreign companies. The utilities also strengthen the yield, which, for what amounts to a growth investment, comes out to a very respectable 1.75%. Unfortunately the dividend is paid yearly (on the last business day of the year), so the compounding power is reduced to annual compounding rather than quarterly. Another disappointing aspect to CGW is its low trading volume-it only averages 25.7K a day, so investors must be prepared for a relatively illiquid investment. CGW’s expense ratio of 0.65% is only slightly higher than FIW and PHO’s, but unfortunately it trades at 0.3% premium to its net asset value. This is cause for concern, but I do think that CGW deserves a premium due to its foreign holdings. Anyone who has owns foreign securities knows there is quite often an ADR fee and, quite possibly, taxes on foreign dividends. Finally, CGW owns securities that are otherwise difficult for Americans to own. For example take Guangdong Investments, which is a major provider of water in Hong Kong and China, but only trades on Hong Kong’s exchange. Finally, Schwab investors interested in water investments should give CGW a particularly close look. This is because CGW trades for free. I use Schwab, and the feature is wonderful-I have legitimately bought one share of CGW and it worked as advertised. This makes it easy to buy a few shares every payday without having to worry too much about trading fees or market timing. Out of all the options, I believe CGW to be the best. PHO: On the surface, PowerShares’ domestic water ETF seems to share a great deal in common with FIW. It has a small utility component (13%), is comprised of 35 holdings (vs. 37 for FIW), and is generally composed of industrial, life science, and materials companies. Because of this, like FIW, PHO is weighted more towards growth stocks, and has a very low dividend (0.60%). Source: Invesco However, a shallow dive into the holdings reveals a strong emphasis on energy. PHO has 15% of its assets in First Solar (NASDAQ: FSLR ) and SunEdison (NYSE: SUNE ); all together over 20% of the fund is devoted to renewable energy. Overall, I understand what PowerShares is aiming for-hydroelectric is entirely reliant on water, and oil and gas use and pollute water during extraction and refinement. Of course, PHO does have significant holdings in companies more closely related to water, such as Pentair, Ecolab (NYSE: ECL ), American Water Works, Xylem, and Valmont (NYSE: VMI ). That said, a 20% weighting in alternative energy seems like overkill to me. I would prefer to have higher weightings in desalination, filtration, pumping, irrigation, and metering, with 5-10% devoted to alternative energy. Additionally, given that the top 10 holdings account for 61% of the fund, I would favor a more balanced allocation to lower volatility and risk. Source: Invesco On the plus side, PHO’s expense ratio is a relatively reasonable 0.61%, which is slightly higher than FIW’s, but would be the lowest if/when FIW’s new fee program kicks in. As of now, PHO does not trade at any premium or discount to its net asset value. Perhaps most importantly, PHO’s daily trading volume averages 121K shares, giving it a huge advantage over FIW, CGW, and PIO in terms of liquidity. PIO: PIO is PowerShares’ international water ETF , and its 39 holdings resemble a blend of PHO and CGW. Like PHO, PIO has significant holdings in alternative energy, though the asset are limited to FSLR and SUNE, which account for 10% of the fund. Pentair, Veolia, Suez, and Severn Trent are a few major holdings in common with CGW’s. Source: Invesco Similar to CGW, PIO holds 33% of its assets as domestic companies; additionally, many of the foreign holdings overlap with CGW’s, though PIO’s exposure to the United Kingdom and France are noticeably higher. With utilities accounting for 45% of PIO’s holdings, it has the largest utility weighting of the group. Like CGW, this is a bonus for volatility, though given that people often view water as a fundamental right, I would be wary about putting too much money in utilities operating in left leaning countries. Fortunately for holders of CGW and PIO, many of these utilities, especially Veolia and Suez, are global companies that do business around the world, including the United States. Source: Invesco Despite PIO’s heavy utility holdings, it only yields 1.27%, though the strong dollar could be somewhat to blame for the muted dividend. PIO’s 0.76% expense ratio is very high, and it currently trades at a 0.1% premium to its assets. Additionally, PIO has very low liquidity, as its volume averages only 18.8K a day. Source: Investco CONCLUSION Much like individual water stocks, there are advantages and disadvantages to each of the ETFs. FIW’s holdings are by far my favorite, but if the new expense ratio rolls out, it will difficult to justify paying a 0.84% fee. Water ETFs already have high costs, and I would shy away from paying any more than necessary. At 0.76% cost ratio, PIO isn’t much better, leaving CGW and PHO as the “low fee” water ETFs. For me, PHO’s solar presence is too strong for my liking, though I may eventually buy some shares. PHO has strong liquidity, and I do like their thought processes behind the solar investments. CGW’s holdings are my second favorite behind FIW’s, and it pays an almost 2% dividend. That said, its current 0.3% premium is somewhat concerning, especially given that these specialty ETFs come with high expense ratios. Since I have a Schwab account, and can trade CGW for free, I have decided to pair CGW with individual water stocks. I will likely continue to slowly add to CGW until I reach a full position. I have no immediate plans to buy PHO, but will probably open a moderate position at some point. While there is no absolute winner, I think CGW is the best option. It offers both domestic and international exposure, is very “water focused,” has a reasonable fee structure, and pays the best dividend. That said, despite their underwhelming performance since their inceptions, I expect all of these ETFs to outperform the broader market over time. However, the high costs, low liquidity, and occasional bizarre holdings leave much to be desired. Hopefully as more investors look to invest in water, additional water ETFs with lower fees and higher liquidity will stream into the market. Disclosure: I am/we are long CGW, PNR, VEOEY, LNN, VMI. (More…) I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Biotech Weekly: Position Management And What To Do When You’re In The Red

If a stock that you like drops even though the thesis for holding the stock has not been altered, consider it as an opportunity to add on weakness. BLUE presented a textbook example on Friday of when to add to a position when a stock is acting weak even though the bull thesis remains unchanged. Roka Biosciences may come in with weak Q2 earnings, which would be a great buying opportunity as the thesis is built on H2 sales momentum with the improved listeria assay. Completing thorough due diligence before buying allows you to properly manage your position and provides you the conviction to add to your position on weakness. Welcome to this week’s edition of Biotech Weekly. The past week was rough for biotech investors with the iShares NASDAQ Biotechnology ETF (NASDAQ: IBB ) declining 3.6% and the more small cap SPDR Biotech ETF (NYSEARCA: XBI ) dropping 7.1%. With the rough action, both the IBB (-0.1%) and the XBI (-6.0%) are now down for the quarter, though its important to note that they are both still up significantly year-to-date. XBI data by YCharts With the recent volatility in both small and mid cap names, I’ve seen a number of biotech investors discussing making changes to their portfolios based on the profit/loss of their holdings. While I understand how it can be extremely frustrating to be underwater in a position, it is not smart or logical to make changes to your portfolio based on your unrealized gain/loss, with the one exception being strategic tax-loss trading near the end of the year. While unrealized gain/loss is a measure of how much you have lost or gained in market value since your original investment, it is not a pertinent statistic when considering the proper valuation of a security. I want to use this piece to discuss some of what I believe are important things to consider during the life of a holding and run through a few examples. When You Buy A Stock: By the time you purchase a stock, you should have completed the following tasks: Significant due diligence Review of pipeline assets and science supporting development Identification of near-term catalysts Research on the management team Consideration of the major investors in the stock Acknowledgement of companies with potentially competing treatments Thorough review of upside/downside depending on potential upcoming news Study of the capital structure Examination of the financial statements Understanding of cash runway Determining what the appropriate valuation is for the asset Thesis: From considering these factors above, you should be able to develop a thesis that explains your reasoning for holding the stock. This thesis should cover your belief why the stock will appreciate in value. Example #1: Roka Biosciences (NASDAQ: ROKA ): Back in November 2014, I looked into Roka Biosciences in some detail, but had concluded that it would be best to wait on the sidelines for another earnings report or two given that issues with false positives from the company’s Atlas Listeria LSP Detection Assay would hamper sales. After continuing to watch newsflow surrounding the company, seven months later at the end of June 2015, I highlighted Roka as a top name to buy and presented the following thesis: Pent-up sales demand for the company’s improved listeria assay projected to be cleared in July would fuel sales growth in H2 for this company trading under cash as of its last report with a solid management team and high institutional ownership that has held the stock during past weakness. Example #2: bluebird bio, Inc. (NASDAQ: BLUE ): For the second example, I wanted to present a more mainstream biotech that has experienced some recent significant volatility. Let’s discuss the example of an investor that purchased bluebird on June 24 at $170, the day after the company announced strong pricing for its common stock offering. Let’s present the following thesis that is probably similar to what many investors in bluebird believe: This gene therapy leader with a cash runway into 2018, has an exciting asset in LentiGlobin with two compelling indications (beta-thalassemia major and severe sickle cell disease) and potential data for both indications in December at ASH, an additional late-stage asset in Lenti-D, and numerous immuno-oncology collaborations likely to provide increased newsflow in 2016 presents the opportunity to invest in a new wave of technology progressing towards commercialization. Evaluating Your Position: Managing your position isn’t something that ends after you make a purchase. As an investor, your job has only begun. You are responsible for tracking how newsflow may affect the company and your thesis. If an event happens to disprove your thesis, you likely should be selling out and moving on. If the stock hits what you believe is the fair valuation and no longer presents an attractive risk/reward, you should be reducing/selling your position. Even if the stock has rallied a lot yet still presents a respectable valuation, there is nothing wrong with taking a little bit off the table, as no one has been hurt by taking a little profit. If the stock declines and your thesis remains intact, you should be adding to your position, not dumping your stock (“puking up” your position as traders say). I’ve never been a huge fan of stop losses as they can cause you to sell a stock in a market correction (such as what biotech has been experiencing recently) just because investors are going “risk-off” and not because of any company-specific news. Let’s walk through the two examples. Example #1: Roka Biosciences: Since buying ROKA in mid June, I saw the stock rise approximately 36% into a mid July announcement that the company had indeed received AOAC clearance for its improved listeria assay . I did not trim any of my position off over $3.50, as I firmly believe the stock has substantially more upside than this once the pent-up sales demand is released. I believe the stock has a good chance to return to the $8+ price per share levels where it traded before issues with false positives for its original listeria assay. When I saw the stock fade over the next few weeks, I asked myself if my thesis was still intact. After review, I determined that my thesis was indeed still intact, and the investment was actually derisked slightly given that the company had achieved the AOAC clearance. Given this, I decided to purchase more shares this month. That being said, I have been very clear that I expect Q2 sales to be poor. I started my position before Q2 earnings as I felt the current depressed valuation around cash levels, the AOAC clearance catalyst, and the potential for H2 sales momentum would provide some support and allow me to participate in upside if the company is indeed able to pull a rabbit out of its hat in terms of sales progress in Q2. Should shares drop on weak Q2 earnings, my thesis will remain intact, and this drop would be a great (and potentially last) buying opportunity. Example #2: bluebird bio, Inc.: After bouncing around between $155 and $170 per share after the offering, the stock declined from a high of $168.03 on August 6 to a low of $129.01 only a day later. So, what caused the stock to tank more than 23% in this short period of time? The company had provided its second quarter operating results in a press release on August 6 , but there wasn’t anything particular of note. The thesis I presented above remained fully intact. Selling merely appeared related to a risk-off theme of selling every biotech in sight, especially if they did not have a major catalyst this quarter. There’s no reason to sell the stock just because your profit/loss line in your account now shows you at a loss. An investor that had bought the stock after the most recent offering given the thesis I presented would certainly have been downright confused by the significant drop, but should have taken the drop as a gift and added to the bluebird position. Many investors certainly realized that the stock was being inappropriately beaten down as it proceeded to rally over 25 points in a half-day of trading. What type of stock has a 25-point intraday rally in a weak market? A stock that shouldn’t have been receiving a beating in the first place. Who was selling bluebird below 140? It certainly didn’t make sense for me. Those that had bought recently should have been adding if anything as their investment thesis likely remained intact. Those that bought the stock much lower should have been selling in the $160-170 range if they felt the stock was fairly valued, not dumping shares after a decline over 20% after parts of two trading days. Conclusion: Don’t jump into stocks until completing thorough due diligence. This through due diligence allows you to properly manage your position. Make sure to develop a solid thesis, which you can see play out by tracking newsflow. If a stock that you like and believe presents a reasonable valuation drops even though the thesis for holding the stock has not been altered (as we saw with bluebird on Friday), consider this an opportunity to add to your position on weakness, not blindly dump your shares as the stock declines for no significant company-specific reason Editor’s Note: This article covers one or more stocks trading at less than $1 per share and/or with less than a $100 million market cap. Please be aware of the risks associated with these stocks. Disclosure: I am/we are long ROKA. (More…) I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Kite Pharma, Bluebird Bio Team Up To Fight HPV

Biotechs Kite Pharma (KITE) and Bluebird Bio (BLUE) announced Monday that they’re collaborating on a new treatment for human papillomavirus (HPV), sending both stocks rising. The two companies plan to combine Kite’s expertise with T cell receptors (TCRs), components of cells that regulate the immune response, with Bluebird’s capabilities in gene editing and lentiviruses (harmless viruses that deliver gene therapies). They’re targeting HPV type 16,